These include unresectable/metastatic BRAF-mutated melanoma, metastatic non-small cell lung cancer, BRAF V600E-mutated anaplastic thyroid carcinoma, and pediatric recurrent low-grade gliomas with V600 mutations (Dummer et al., 2020; Busaidy et al., 2022; Chou et al., 2022; Atkins et al., 2023; Bouffet et al., 2023). This evidence concerns the gene BRAF and glioma.